Cytox, a University of Birmingham spin out, has relaunched with a custom-built laboratory, a new management team, and £3.5m ($5.5m) from new and existing backers.
The UK-based biomedical firm went into administration 18 months ago. However, Cytox has now returned following new investments from fund manager SPARK Impact, life science fund Esperante, seed investor Wren Capital, and the University of Birmingham. Biotech investor Jim Mellon also invested.
Cytox has advanced a method of testing for early-stage Alzheimer’s, which was originally…
